Teeka Tiwari just pulled back the curtain on his next “trillion-dollar trade” – psychedelic medicine.

Teeka has been on the money twice already. His last two trillion-dollar ideas were investing in Apple after it launched the iPod in 2003… and buying bitcoin in 2016.

He says psychedelic medicine is the next massive market megatrend in the making. And that it has the potential to hand investors 100 years of S&P 500 returns… in just 18 months.

But what is psychedelic medicine? What is it used for? And why is Teeka so excited?

It’s all in your Weekly Pulse video update at the top of the page. It’s where I (Chris Lowe) and host Tom Beal break down the most important story on our radar for the week.



Chris Lowe
Editor, The Daily Cut and Legacy Inner Circle

P.S. To watch the replay of Teeka’s event all about psychedelic medicine and how to play this emerging megatrend, go here

P.P.S. To catch up on some previous Daily Cut dispatches we’ve written on the topic of psychedelic medicine, click here and here.


Tom Beal: Teeka Tiwari has called this the biggest breakthrough since biotech. Imagine a way for you to grow and protect your wealth, while helping people immensely with depression, post-traumatic stress disorder (PTSD), and saving many people from suicide. That’s our topic for today.

My name is Tom Beal, host of the Weekly Pulse, where we bring to you and break down the biggest wealth-growth story of the week.

I’m here today with the editor of Legacy Inner Circle, Chris Lowe. Chris, how do we kick off today’s conversation?

Chris Lowe: Tom, this week, we’re going to be talking about what Teeka Tiwari, our colleague at Legacy Research, thinks is the biggest breakthrough since biotech. That’s actually one of the quotes he’s had, so this is a really big deal.

What he’s talking about is something called psychedelic medicine. That may sound kind of strange. Psychedelics are often associated with the 1960s and with the hippie movement. But this has nothing to do with that.

So today, I thought we’d talk about what psychedelic medicine is. Then we’ll talk about what it’s used for, and why Teeka is so excited about this new breakthrough in medicine.

Today’s episode is brought to you by Legacy Inner Circle. That’s where Chris Lowe is able to peer into the model portfolios and, in essence, into the minds of the experts within Legacy Research Group, and bring to you on a weekly basis, as a member of Legacy Inner Circle, the biggest and best ideas that have the potential to grow and protect your wealth at rates that are not only admirable, but bragworthy.

We have a special offer for you. Click the link below. Go learn more about Legacy Inner Circle. See this amazing offer. Take advantage of it, and join us inside the members area, as well as the members-only iOS and Android app.

We know it will be highly beneficial for you in growing and protecting your wealth in the upcoming days, weeks, months, years, and decades. See you there.

Now, back to this week’s episode.

Tom: Chris, it reminds me of Prohibition of the past, where alcohol was illegal. Then it became legal. And then cannabis, which was illegal and now is becoming legal in many states. So this is another aspect of that that I’m excited to discuss today.

Chris: Tom, it’s a really good point. This is another of those brand-new markets that’s just opening up. It’s really rare. Cannabis started to become legal in certain states in the U.S. and then across Canada. It’s just this once-in-a-lifetime opportunity.

Now, when we say once-in-a-lifetime opportunity, it sounds clichéd. But this really is. You have these substances, compounds that are illegal, thanks to some pretty dodgy federal government stomping all over people’s rights. And then suddenly, they become legal.

And you’re right. Cannabis did this. And now, psychedelic medicine is doing the same thing.

For folks who aren’t familiar with that term, what is psychedelic medicine? It’s therapeutic compounds that have been isolated from psychedelic drugs. These include things like MDMA, which is the key ingredient of a party drug that people may be familiar with called ecstasy. And we also have psilocybin, which is the active compound in certain types of mushrooms, often called magic mushrooms. And even a close cousin of ketamine, which is a party drug, called Super K.

If you’re at a party on the streets in America, or Europe, where I am, you can buy these as party drugs. But actually, researchers are finding out that the compounds they contain have these really powerful properties.

So what are these things used for? This is where it gets really interesting, Tom. Because the FDA, the Food and Drug Administration, which is responsible for green-lighting new therapies in the U.S., has granted breakthrough therapy status to MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD).

Tom, I know you served in the Marines. 20 active duty and retired military personnel take their own lives every day. That sounded shocking to me. These compounds used with therapy are helping folks get over that type of trauma in their lives.

Tom: That’s why this topic excites me so much. Yes, I have a personal vested interest, being someone who served in the United States Marine Corps. And also in witnessing the amount of people that are choosing to take their lives because of post-traumatic stress disorder and other things.

If this can help people get out of that dark spot they’re in, to find some more light at the end of the tunnel and live their life, this is really exciting and a huge breakthrough for me.

How can this help you grow and protect your wealth in the future? That’s why we’re here today. If you can tie in helping people in a great way with this new thing that used to be illegal and is now not illegal… and it can help people in tremendous ways… and you can grow and protect your wealth, it’s a win on all sides, from my perspective.

Chris: And it’s not just PTSD that these compounds are being used to treat. It’s also depression, which is a really big problem across the world.

The FDA has also granted breakthrough therapy designation for psilocybin. That’s the compound from magic mushrooms. That’s to treat treatment-resistant depression (TRD), which means that regular pharmaceutical drugs aren’t working on these folks. But with therapy-assisted psilocybin, they can actually get beyond that depression.

This is already breaking into the mainstream, Tom. It’s amazing how fast this is moving. Johnson & Johnson (JNJ), the pharmaceutical giant, recently released its own FDA-approved drug called Spravato to treat people suffering from depression.

That is using a compound from a close cousin of a party drug called ketamine to treat depression. It’s a fast-acting nasal spray. And that’s also getting FDA approval, moving into the mainstream, and being effective in treating depression, which is very, very exciting.

And, Tom, just to your point about military personnel in the U.S., active and retired. The U.S. Department of Veterans Affairs has approved ketamine for the treatment of PTSD.

These are huge breakthroughs. These illnesses – PTSD and depression – cause a lot of suffering, as you know. So as Teeka says, these are the biggest breakthroughs since biotech, because they’re treating these mental health issues that have been so difficult to treat up to now.

Tom: So, Chris, now that we’re aware of this and it’s becoming more mainstream, how and where would you recommend the viewers of The Weekly Pulse research this and see how it could be a component in growing and protecting their wealth in the future?

Chris: That’s a great question, Tom. Look, this is very early on still, in terms of being investible. We did have some success at Legacy Research. Subscribers of another of our analysts, Nick Giambruno over at Casey Research, had the chance to make a gain on a tiny psychedelic medicine stock called Mind Medicine (MMED) last year.

Nick recommended it to his Crisis Investing subscribers in March 2020. When he sent out a sell alert in December 2020, it was up 1,282%. I remember writing about it last December. It was the best-performing stock across all of Legacy last year.


Now, Teeka has set up a new advisory service called Palm Beach Special Opportunities to look at the psychedelic medicine trend and other trends in the future. That’s how excited he is.

He has brought on Mike Zapolin, who’s known as the “psychedelic concierge to the stars.” He’s a former Wall Street banker, who has been featured in Vice and Playboy and Fox News. He’s been in this space for a long time. He and Teeka are really digging into these tiny stocks.

Right now, Tom, the universe of stocks in this space is very small. These aren’t major stocks trading on exchanges. So this is really something for the radar right now.

Teeka will be looking at these a lot more. And we’ll have some links below, Tom. If anyone wants to find out more about psychedelic medicine, I think the best thing right now is to click on the links we provide below.

Teeka had a live event last Thursday. He revealed a lot more details than we’re able to go into here. And he had his new right-hand man, Mike Zapolin, on there, along with a bunch of stars that have gone down the road of psychedelic treatments. That’s a really interesting replay that folks can catch.

And then, it’s just a matter of watch this space. There’s going to be small stocks getting bigger, and we’ll be covering them in the weeks and months ahead.

Right now, there isn’t a specific recommendation I’m going to pass on, other than to catch up on Teeka’s event. He’s going to have a lot more details for folks who want to dig into this trend some more.

[Click here to watch the replay of Teeka’s “Third Trillion-Dollar Trade” event.]

Tom: Wow! That is helpful. I know some people who did have depression and some serious issues, PTSD and others, a whole bunch of issues. They went down the psychedelic path. I’ve never gone that path, but I’ve heard friends say it changed their life.

So I’m excited that this is something that can be beneficial to those needing it for depression and the things we discussed.

But I’m also excited about it being something to have on the radar for me and all the viewers of The Weekly Pulse to say, “Okay, let me start doing some research.”

What’s the old saying? Skate to where the puck is going, not where it is or where it’s been. So this is where the puck is going. And there’s a great way to possibly grow and protect your wealth.

And the other thing is, if Teeka is excited about this, that gets me super excited. I’ve done very well following what Teeka recommends. And I think many here watching this can agree. So that gets me even more excited, that there’s a way to see how and what Teeka is doing with this new possibility. So thanks for sharing that with us today, Chris.

Chris: Tom, one last thing before we sign off. Teeka says this is going to be a $3 trillion industry. That’s because that’s the kind of spend that’s happening right now on PTSD and depression, two of the biggest mental health issues in the U.S.

So this market is going to take a huge chunk out of that overall market of $3 trillion.

So this really is, as you say, where the puck is going, in terms of mental health. Teeka is convinced about it. I have seen him very excited about things before, like crypto back in 2016, when he was recommending bitcoin. He has put a lot of work into this. He’s partnered up with Mike Zapolin, who’s one of the leaders in this space.

And he’s really putting his name and his reputation behind this being one of the next big market megatrends that a lot of people are going to be hearing about in one year’s time, two years’ time.

So you heard it here first. For a lot of folks viewing, this will be the first time they’ve heard it. But it won’t be the last.

Tom: Chris, now it’s on my radar. I’m going to make a little ticker to start doing some research and keep my eyes open. And most importantly, plug into what Teeka’s saying. Because as we all know, what Teeka says generally work. So I’m going to be listening very closely.

Thanks for bringing that to my and the viewers of the Weekly Pulse’s attention today, Chris. We’re excited to look further into that.

Chris: Thanks, Tom.

Tom: If you’re still here, that means you’re not yet part of Legacy Inner Circle. That’s where Chris Lowe, the editor, has the unique perspective to look into all the Legacy Research model portfolios. Teeka is well known for bitcoin and cryptocurrencies. But he also, as you just heard today, has his eye on where the puck is going to help people grow and protect their wealth. And this is one of the many areas that has him super excited.

So, Chris, you have advance looks into all these expert’s minds, per se, and their model portfolios to bring people inside Legacy Inner Circle. How can you stress the importance of being inside and getting the perspectives that you’re able to share from these experts, as a Legacy Inner Circle member?

Chris: Yes, Tom, my job is to communicate the big ideas that folks like Teeka… Jeff Brown, our tech expert… I mentioned Nick Giambruno at Casey Research… Dave Forest, our commodities expert… Jason Bodner, a former Wall Street trader.

All of these guys work under the umbrella of Legacy Research. That’s an independent group of publishing companies that have come together in an alliance around contrarian ideas that are designed to help folks really move the needle on their wealth.

Now, you can subscribe to one of our paid advisories. Typically, it’ll focus in on one market niche. I mentioned Jeff Brown. He covers tech stocks, bleeding-edge tech, artificial intelligence (AI), self-driving cars, cloud computing, nuclear fusion.

Teeka, on the other hand, is a crypto guy a lot of the time. He also has some trading services.

Nick Giambruno is a crisis investor. He travels around the world looking for beaten-down assets in places where there’s a crisis going on.

All of them have totally different styles. But all of them are making big gains for their readers. I mentioned Nick Giambruno handing his readers the chance to make a gain of 1,282%. I mean, this is hedge fund-smashing returns, Tom.

My job is to bring the best of those ideas each week. We publish Legacy Inner Circle every Friday. It’s an easy-to-digest briefing of what is the big, compelling idea that needs to be on folks’ radars that week.

And there’s many of them out there, Tom. I think of my job as like a curator of art. You’re trying to pick the one idea that’s really going to get people excited, that really has that profit potential.

That’s what Legacy Inner Circle is all about. You’re going to get ideas from the whole team. You’re going to get ideas across the gamut of asset classes and different market sectors. We look at trading strategies that work, investing strategies, international stuff, crypto, you name it. As long as one of our analysts is banging the table on an idea, we’re going to bring that idea to our subscribers.

So if you’re new to investing and you really want to dip a toe into different areas of the market… or you want to just see what excites you as an investor… or you just want to stay informed of the best ideas we publish… and you don’t want to have to wade through all of those research reports, which can be quite big and quite dense sometimes… Legacy Inner Circle is a great start.

You get a view inside what is really popping in those portfolios and what guys like Teeka and Jeff are really, really excited about.

I have them on speed dial. I’ve known them for a long time. I’m not the expert. I am the communicator between the experts and our readers. That’s my job.

Tom, you’re on board to make sure that readers and viewers get the most out of those recommendations. A lot of folks can get an idea, but it’s acting on it, sticking with it.

So we do a lot of that, too. As I said, we publish every week. And we make sure that folks not only get the ideas, but also have the courage and the knowledge to act on them.

Tom: Great summary, Chris. The experts have teams of people that do the research with them. So you’re tapping into not just the experts, but the teams that they have. So you’re literally getting hundreds of hours curated by Chris. There are so many moving parts.

And, Chris, we’re getting feedback from friends that are tapping into the knowledge that you bring to them, like, “There’s so much happening. I don’t have the time to dedicate 40, 50, 60 hours a week to learn this stuff.”

Well, guess what? Those experts and their teams are doing it for you. And Chris is curating for you the greatest, biggest idea, to get that on your radar.

And it’s at a price that’s absolutely absurd. It’s extremely reasonable. We have a special for you as a Weekly Pulse viewer.

So click the link below, go check it out. We look forward to seeing you inside the members-only area, as well as the members-only app on the iOS and Android devices.

Chris, thank you for what you do, bringing this to my and the Legacy Inner Circle members’ attention each week.

And we look forward to seeing you as a Weekly Pulse viewer inside Legacy Inner Circle. We know it will be a wise choice, that you’ll be one of our many testimonials in the future.

Thanks again, Chris.

Chris: Thanks, Tom.

Not yet a Legacy Inner Circle member? Join here.